PandemieGrippaleV1, PascalFrancis, Corpus, bibRecord, 000403

2009 Pandemic Influenza A Virus Subtype H1N1 Vaccination in Africa-Successes and Challenges

Identifieur interne : 000403 ( PascalFrancis/Corpus ); précédent : 000402; suivant : 000404

2009 Pandemic Influenza A Virus Subtype H1N1 Vaccination in Africa-Successes and Challenges

Auteurs : Richard Mihigo ; Claudia Vivas Torrealba ; Kanokporn Coninx ; Deo Nshimirimana ; Marie Paule Kieny ; Peter Carrasco ; Lisa Hedman ; Marc-Alain Widdowson

Source :

The Journal of infectious diseases [ 0022-1899 ] ; 2012.

RBID : Pascal:13-0059247

Descripteurs français

Pascal (Inist)
- Soustype, Vaccination, Afrique, Infection, Virus grippal A(H1N1).

English descriptors

KwdEn :
- Africa, Infection, Influenzavirus A(H1N1), Subtype, Vaccination.

Abstract

To provide vaccination against infection due to 2009 pandemic influenza A virus subtype H1N1 (A[H1N1] pdm09) to resource-constrained countries with otherwise very little access to the A(H1N1)pdm09 vaccine, the World Health Organization (WHO) coordinated distribution of donated vaccine to selected countries worldwide, including those in Africa. From February through November 2010, 32.2 million doses were delivered to 34 countries in Africa. Of the 19.2 million doses delivered to countries that reported their vaccination activities to WHO, 12.2 million doses (64%) were administered. Population coverage in these countries varied from 0.4% to 11%, with a median coverage of 4%. All countries targeted pregnant women (median proportion of all vaccine doses administered [mpv], 21% [range, 4%-72%]) and healthcare workers (mpv, 9% [range, 1%-73%]). Fourteen of 19 countries targeted persons with chronic conditions (mpv, 26% [range, 5%-66%]) and 10 of 19 countries vaccinated children (mpv, 54% [range, 17%-75%]). Most vaccine was distributed after peak A(H1N1)pdm09 transmission in the region. The frequency and severity of adverse events were consistent with those recorded after other inactivated influenza vaccines. Pandemic preparedness plans will need to include strategies to ensure more-rapid procedures to identify vaccine supplies and distribute and import vaccines to countries that may bear the brunt of a future pandemic.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0022-1899`
A02	`01`			`@0 JIDIAQ`
A03		`1`		`@0 J. infect. dis.`
A05				`@2 206`
A06				`@3 SUP1`
A08	`01`	`1`	`ENG`	`@1 2009 Pandemic Influenza A Virus Subtype H1N1 Vaccination in Africa-Successes and Challenges`
A09	`01`	`1`	`ENG`	`@1 INFLUENZA IN AFRICA`
A11	`01`	`1`		`@1 MIHIGO (Richard)`
A11	`02`	`1`		`@1 VIVAS TORREALBA (Claudia)`
A11	`03`	`1`		`@1 CONINX (Kanokporn)`
A11	`04`	`1`		`@1 NSHIMIRIMANA (Deo)`
A11	`05`	`1`		`@1 KIENY (Marie Paule)`
A11	`06`	`1`		`@1 CARRASCO (Peter)`
A11	`07`	`1`		`@1 HEDMAN (Lisa)`
A11	`08`	`1`		`@1 WIDDOWSON (Marc-Alain)`
A12	`01`	`1`		`@1 KATZ (Mark A.) @9 ed.`
A12	`02`	`1`		`@1 SCHOUB (Barry D.) @9 ed.`
A12	`03`	`1`		`@1 HERAUD (Jean-Michel) @9 ed.`
A12	`04`	`1`		`@1 WIDDOWSON (Marc-Alain) @9 ed.`
A14	`01`			`@1 World Health Organization Regional Office for Africa @2 Brazzaville @3 COG @Z 1 aut. @Z 4 aut.`
A14	`02`			`@1 World Health Organization @2 Geneva @3 CHE @Z 2 aut. @Z 3 aut. @Z 5 aut. @Z 6 aut. @Z 7 aut.`
A14	`03`			`@1 Centers for Disease Control and Prevention @2 Atlanta @3 GEO @Z 8 aut.`
A15	`01`			`@1 Global Disease Detection Division, Centers for Disease Control and Prevention @2 Nairobi @3 KEN @Z 1 aut.`
A15	`02`			`@1 University of the Witwatersrand @2 Johannesburg @3 ZAF @Z 2 aut.`
A15	`03`			`@1 National Influenza Center, Institut Pasteur de Madagascar @2 Antanarivo @3 MDG @Z 3 aut.`
A15	`04`			`@1 Centre for Vaccines and Immunology, National Institute for Communicable Diseases, National Health Laboratory Service @2 Johannesburg @3 ZAF @Z 2 aut.`
A15	`05`			`@1 International Epidemiology and Research Team, Epidemiology and Prevention Branch Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention @2 Atlanta, GA @3 USA @Z 4 aut.`
A20				`@2 S22-S28`
A21				`@1 2012`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 2052 @5 354000505499230030`
A44				`@0 0000 @1 © 2013 INIST-CNRS. All rights reserved.`
A45				`@0 17 ref.`
A47	`01`	`1`		`@0 13-0059247`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 The Journal of infectious diseases`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 To provide vaccination against infection due to 2009 pandemic influenza A virus subtype H1N1 (A[H1N1] pdm09) to resource-constrained countries with otherwise very little access to the A(H1N1)pdm09 vaccine, the World Health Organization (WHO) coordinated distribution of donated vaccine to selected countries worldwide, including those in Africa. From February through November 2010, 32.2 million doses were delivered to 34 countries in Africa. Of the 19.2 million doses delivered to countries that reported their vaccination activities to WHO, 12.2 million doses (64%) were administered. Population coverage in these countries varied from 0.4% to 11%, with a median coverage of 4%. All countries targeted pregnant women (median proportion of all vaccine doses administered [mpv], 21% [range, 4%-72%]) and healthcare workers (mpv, 9% [range, 1%-73%]). Fourteen of 19 countries targeted persons with chronic conditions (mpv, 26% [range, 5%-66%]) and 10 of 19 countries vaccinated children (mpv, 54% [range, 17%-75%]). Most vaccine was distributed after peak A(H1N1)pdm09 transmission in the region. The frequency and severity of adverse events were consistent with those recorded after other inactivated influenza vaccines. Pandemic preparedness plans will need to include strategies to ensure more-rapid procedures to identify vaccine supplies and distribute and import vaccines to countries that may bear the brunt of a future pandemic.
C02	`01`	`X`		`@0 002A05`
C02	`02`	`X`		`@0 002B05`
C03	`01`	`X`	`FRE`	`@0 Soustype @5 05`
C03	`01`	`X`	`ENG`	`@0 Subtype @5 05`
C03	`01`	`X`	`SPA`	`@0 Subtipo @5 05`
C03	`02`	`X`	`FRE`	`@0 Vaccination @5 06`
C03	`02`	`X`	`ENG`	`@0 Vaccination @5 06`
C03	`02`	`X`	`SPA`	`@0 Vacunación @5 06`
C03	`03`	`X`	`FRE`	`@0 Afrique @2 NG @5 07`
C03	`03`	`X`	`ENG`	`@0 Africa @2 NG @5 07`
C03	`03`	`X`	`SPA`	`@0 Africa @2 NG @5 07`
C03	`04`	`X`	`FRE`	`@0 Infection @5 08`
C03	`04`	`X`	`ENG`	`@0 Infection @5 08`
C03	`04`	`X`	`SPA`	`@0 Infección @5 08`
C03	`05`	`X`	`FRE`	`@0 Virus grippal A(H1N1) @4 CD @5 96`
C03	`05`	`X`	`ENG`	`@0 Influenzavirus A(H1N1) @4 CD @5 96`
N21				`@1 035`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 13-0059247 INIST
ET :	2009 Pandemic Influenza A Virus Subtype H1N1 Vaccination in Africa-Successes and Challenges
AU :	MIHIGO (Richard); VIVAS TORREALBA (Claudia); CONINX (Kanokporn); NSHIMIRIMANA (Deo); KIENY (Marie Paule); CARRASCO (Peter); HEDMAN (Lisa); WIDDOWSON (Marc-Alain); KATZ (Mark A.); SCHOUB (Barry D.); HERAUD (Jean-Michel); WIDDOWSON (Marc-Alain)
AF :	World Health Organization Regional Office for Africa/Brazzaville/Congo (1 aut., 4 aut.); World Health Organization/Geneva/Suisse (2 aut., 3 aut., 5 aut., 6 aut., 7 aut.); Centers for Disease Control and Prevention/Atlanta/Géorgie (8 aut.); Global Disease Detection Division, Centers for Disease Control and Prevention/Nairobi/Kenya (1 aut.); University of the Witwatersrand/Johannesburg/Afrique du Sud (2 aut.); National Influenza Center, Institut Pasteur de Madagascar/Antanarivo/Madagascar (3 aut.); Centre for Vaccines and Immunology, National Institute for Communicable Diseases, National Health Laboratory Service/Johannesburg/Afrique du Sud (2 aut.); International Epidemiology and Research Team, Epidemiology and Prevention Branch Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention/Atlanta, GA/Etats-Unis (4 aut.)
DT :	Publication en série; Niveau analytique
SO :	The Journal of infectious diseases; ISSN 0022-1899; Coden JIDIAQ; Royaume-Uni; Da. 2012; Vol. 206; No. SUP1; S22-S28; Bibl. 17 ref.
LA :	Anglais
EA :	To provide vaccination against infection due to 2009 pandemic influenza A virus subtype H1N1 (A[H1N1] pdm09) to resource-constrained countries with otherwise very little access to the A(H1N1)pdm09 vaccine, the World Health Organization (WHO) coordinated distribution of donated vaccine to selected countries worldwide, including those in Africa. From February through November 2010, 32.2 million doses were delivered to 34 countries in Africa. Of the 19.2 million doses delivered to countries that reported their vaccination activities to WHO, 12.2 million doses (64%) were administered. Population coverage in these countries varied from 0.4% to 11%, with a median coverage of 4%. All countries targeted pregnant women (median proportion of all vaccine doses administered [mpv], 21% [range, 4%-72%]) and healthcare workers (mpv, 9% [range, 1%-73%]). Fourteen of 19 countries targeted persons with chronic conditions (mpv, 26% [range, 5%-66%]) and 10 of 19 countries vaccinated children (mpv, 54% [range, 17%-75%]). Most vaccine was distributed after peak A(H1N1)pdm09 transmission in the region. The frequency and severity of adverse events were consistent with those recorded after other inactivated influenza vaccines. Pandemic preparedness plans will need to include strategies to ensure more-rapid procedures to identify vaccine supplies and distribute and import vaccines to countries that may bear the brunt of a future pandemic.
CC :	002A05; 002B05
FD :	Soustype; Vaccination; Afrique; Infection; Virus grippal A(H1N1)
ED :	Subtype; Vaccination; Africa; Infection; Influenzavirus A(H1N1)
SD :	Subtipo; Vacunación; Africa; Infección
LO :	INIST-2052.354000505499230030
ID :	13-0059247

Links to Exploration step

Pascal:13-0059247

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">2009 Pandemic Influenza A Virus Subtype H1N1 Vaccination in Africa-Successes and Challenges</title>
<author><name sortKey="Mihigo, Richard" sort="Mihigo, Richard" uniqKey="Mihigo R" first="Richard" last="Mihigo">Richard Mihigo</name>
<affiliation><inist:fA14 i1="01"><s1>World Health Organization Regional Office for Africa</s1>
<s2>Brazzaville</s2>
<s3>COG</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Vivas Torrealba, Claudia" sort="Vivas Torrealba, Claudia" uniqKey="Vivas Torrealba C" first="Claudia" last="Vivas Torrealba">Claudia Vivas Torrealba</name>
<affiliation><inist:fA14 i1="02"><s1>World Health Organization</s1>
<s2>Geneva</s2>
<s3>CHE</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Coninx, Kanokporn" sort="Coninx, Kanokporn" uniqKey="Coninx K" first="Kanokporn" last="Coninx">Kanokporn Coninx</name>
<affiliation><inist:fA14 i1="02"><s1>World Health Organization</s1>
<s2>Geneva</s2>
<s3>CHE</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Nshimirimana, Deo" sort="Nshimirimana, Deo" uniqKey="Nshimirimana D" first="Deo" last="Nshimirimana">Deo Nshimirimana</name>
<affiliation><inist:fA14 i1="01"><s1>World Health Organization Regional Office for Africa</s1>
<s2>Brazzaville</s2>
<s3>COG</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kieny, Marie Paule" sort="Kieny, Marie Paule" uniqKey="Kieny M" first="Marie Paule" last="Kieny">Marie Paule Kieny</name>
<affiliation><inist:fA14 i1="02"><s1>World Health Organization</s1>
<s2>Geneva</s2>
<s3>CHE</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Carrasco, Peter" sort="Carrasco, Peter" uniqKey="Carrasco P" first="Peter" last="Carrasco">Peter Carrasco</name>
<affiliation><inist:fA14 i1="02"><s1>World Health Organization</s1>
<s2>Geneva</s2>
<s3>CHE</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hedman, Lisa" sort="Hedman, Lisa" uniqKey="Hedman L" first="Lisa" last="Hedman">Lisa Hedman</name>
<affiliation><inist:fA14 i1="02"><s1>World Health Organization</s1>
<s2>Geneva</s2>
<s3>CHE</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Widdowson, Marc Alain" sort="Widdowson, Marc Alain" uniqKey="Widdowson M" first="Marc-Alain" last="Widdowson">Marc-Alain Widdowson</name>
<affiliation><inist:fA14 i1="03"><s1>Centers for Disease Control and Prevention</s1>
<s2>Atlanta</s2>
<s3>GEO</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">13-0059247</idno>
<date when="2012">2012</date>
<idno type="stanalyst">PASCAL 13-0059247 INIST</idno>
<idno type="RBID">Pascal:13-0059247</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000403</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">2009 Pandemic Influenza A Virus Subtype H1N1 Vaccination in Africa-Successes and Challenges</title>
<author><name sortKey="Mihigo, Richard" sort="Mihigo, Richard" uniqKey="Mihigo R" first="Richard" last="Mihigo">Richard Mihigo</name>
<affiliation><inist:fA14 i1="01"><s1>World Health Organization Regional Office for Africa</s1>
<s2>Brazzaville</s2>
<s3>COG</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Vivas Torrealba, Claudia" sort="Vivas Torrealba, Claudia" uniqKey="Vivas Torrealba C" first="Claudia" last="Vivas Torrealba">Claudia Vivas Torrealba</name>
<affiliation><inist:fA14 i1="02"><s1>World Health Organization</s1>
<s2>Geneva</s2>
<s3>CHE</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Coninx, Kanokporn" sort="Coninx, Kanokporn" uniqKey="Coninx K" first="Kanokporn" last="Coninx">Kanokporn Coninx</name>
<affiliation><inist:fA14 i1="02"><s1>World Health Organization</s1>
<s2>Geneva</s2>
<s3>CHE</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Nshimirimana, Deo" sort="Nshimirimana, Deo" uniqKey="Nshimirimana D" first="Deo" last="Nshimirimana">Deo Nshimirimana</name>
<affiliation><inist:fA14 i1="01"><s1>World Health Organization Regional Office for Africa</s1>
<s2>Brazzaville</s2>
<s3>COG</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kieny, Marie Paule" sort="Kieny, Marie Paule" uniqKey="Kieny M" first="Marie Paule" last="Kieny">Marie Paule Kieny</name>
<affiliation><inist:fA14 i1="02"><s1>World Health Organization</s1>
<s2>Geneva</s2>
<s3>CHE</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Carrasco, Peter" sort="Carrasco, Peter" uniqKey="Carrasco P" first="Peter" last="Carrasco">Peter Carrasco</name>
<affiliation><inist:fA14 i1="02"><s1>World Health Organization</s1>
<s2>Geneva</s2>
<s3>CHE</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hedman, Lisa" sort="Hedman, Lisa" uniqKey="Hedman L" first="Lisa" last="Hedman">Lisa Hedman</name>
<affiliation><inist:fA14 i1="02"><s1>World Health Organization</s1>
<s2>Geneva</s2>
<s3>CHE</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Widdowson, Marc Alain" sort="Widdowson, Marc Alain" uniqKey="Widdowson M" first="Marc-Alain" last="Widdowson">Marc-Alain Widdowson</name>
<affiliation><inist:fA14 i1="03"><s1>Centers for Disease Control and Prevention</s1>
<s2>Atlanta</s2>
<s3>GEO</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">The Journal of infectious diseases</title>
<title level="j" type="abbreviated">J. infect. dis.</title>
<idno type="ISSN">0022-1899</idno>
<imprint><date when="2012">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">The Journal of infectious diseases</title>
<title level="j" type="abbreviated">J. infect. dis.</title>
<idno type="ISSN">0022-1899</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Africa</term>
<term>Infection</term>
<term>Influenzavirus A(H1N1)</term>
<term>Subtype</term>
<term>Vaccination</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Soustype</term>
<term>Vaccination</term>
<term>Afrique</term>
<term>Infection</term>
<term>Virus grippal A(H1N1)</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">To provide vaccination against infection due to 2009 pandemic influenza A virus subtype H1N1 (A[H1N1] pdm09) to resource-constrained countries with otherwise very little access to the A(H1N1)pdm09 vaccine, the World Health Organization (WHO) coordinated distribution of donated vaccine to selected countries worldwide, including those in Africa. From February through November 2010, 32.2 million doses were delivered to 34 countries in Africa. Of the 19.2 million doses delivered to countries that reported their vaccination activities to WHO, 12.2 million doses (64%) were administered. Population coverage in these countries varied from 0.4% to 11%, with a median coverage of 4%. All countries targeted pregnant women (median proportion of all vaccine doses administered [mpv], 21% [range, 4%-72%]) and healthcare workers (mpv, 9% [range, 1%-73%]). Fourteen of 19 countries targeted persons with chronic conditions (mpv, 26% [range, 5%-66%]) and 10 of 19 countries vaccinated children (mpv, 54% [range, 17%-75%]). Most vaccine was distributed after peak A(H1N1)pdm09 transmission in the region. The frequency and severity of adverse events were consistent with those recorded after other inactivated influenza vaccines. Pandemic preparedness plans will need to include strategies to ensure more-rapid procedures to identify vaccine supplies and distribute and import vaccines to countries that may bear the brunt of a future pandemic.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0022-1899</s0>
</fA01>
<fA02 i1="01"><s0>JIDIAQ</s0>
</fA02>
<fA03 i2="1"><s0>J. infect. dis.</s0>
</fA03>
<fA05><s2>206</s2>
</fA05>
<fA06><s3>SUP1</s3>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>2009 Pandemic Influenza A Virus Subtype H1N1 Vaccination in Africa-Successes and Challenges</s1>
</fA08>
<fA09 i1="01" i2="1" l="ENG"><s1>INFLUENZA IN AFRICA</s1>
</fA09>
<fA11 i1="01" i2="1"><s1>MIHIGO (Richard)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>VIVAS TORREALBA (Claudia)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>CONINX (Kanokporn)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>NSHIMIRIMANA (Deo)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>KIENY (Marie Paule)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>CARRASCO (Peter)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>HEDMAN (Lisa)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>WIDDOWSON (Marc-Alain)</s1>
</fA11>
<fA12 i1="01" i2="1"><s1>KATZ (Mark A.)</s1>
<s9>ed.</s9>
</fA12>
<fA12 i1="02" i2="1"><s1>SCHOUB (Barry D.)</s1>
<s9>ed.</s9>
</fA12>
<fA12 i1="03" i2="1"><s1>HERAUD (Jean-Michel)</s1>
<s9>ed.</s9>
</fA12>
<fA12 i1="04" i2="1"><s1>WIDDOWSON (Marc-Alain)</s1>
<s9>ed.</s9>
</fA12>
<fA14 i1="01"><s1>World Health Organization Regional Office for Africa</s1>
<s2>Brazzaville</s2>
<s3>COG</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>World Health Organization</s1>
<s2>Geneva</s2>
<s3>CHE</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Centers for Disease Control and Prevention</s1>
<s2>Atlanta</s2>
<s3>GEO</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA15 i1="01"><s1>Global Disease Detection Division,  Centers for Disease Control and Prevention</s1>
<s2>Nairobi</s2>
<s3>KEN</s3>
<sZ>1 aut.</sZ>
</fA15>
<fA15 i1="02"><s1>University of the Witwatersrand</s1>
<s2>Johannesburg</s2>
<s3>ZAF</s3>
<sZ>2 aut.</sZ>
</fA15>
<fA15 i1="03"><s1>National Influenza Center, Institut Pasteur de Madagascar</s1>
<s2>Antanarivo</s2>
<s3>MDG</s3>
<sZ>3 aut.</sZ>
</fA15>
<fA15 i1="04"><s1>Centre for Vaccines and Immunology, National Institute for Communicable Diseases, National Health Laboratory Service</s1>
<s2>Johannesburg</s2>
<s3>ZAF</s3>
<sZ>2 aut.</sZ>
</fA15>
<fA15 i1="05"><s1>International Epidemiology and Research Team, Epidemiology and Prevention Branch Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention</s1>
<s2>Atlanta, GA</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</fA15>
<fA20><s2>S22-S28</s2>
</fA20>
<fA21><s1>2012</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>2052</s2>
<s5>354000505499230030</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2013 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>17 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>13-0059247</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>The Journal of infectious diseases</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>To provide vaccination against infection due to 2009 pandemic influenza A virus subtype H1N1 (A[H1N1] pdm09) to resource-constrained countries with otherwise very little access to the A(H1N1)pdm09 vaccine, the World Health Organization (WHO) coordinated distribution of donated vaccine to selected countries worldwide, including those in Africa. From February through November 2010, 32.2 million doses were delivered to 34 countries in Africa. Of the 19.2 million doses delivered to countries that reported their vaccination activities to WHO, 12.2 million doses (64%) were administered. Population coverage in these countries varied from 0.4% to 11%, with a median coverage of 4%. All countries targeted pregnant women (median proportion of all vaccine doses administered [mpv], 21% [range, 4%-72%]) and healthcare workers (mpv, 9% [range, 1%-73%]). Fourteen of 19 countries targeted persons with chronic conditions (mpv, 26% [range, 5%-66%]) and 10 of 19 countries vaccinated children (mpv, 54% [range, 17%-75%]). Most vaccine was distributed after peak A(H1N1)pdm09 transmission in the region. The frequency and severity of adverse events were consistent with those recorded after other inactivated influenza vaccines. Pandemic preparedness plans will need to include strategies to ensure more-rapid procedures to identify vaccine supplies and distribute and import vaccines to countries that may bear the brunt of a future pandemic.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002A05</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B05</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Soustype</s0>
<s5>05</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Subtype</s0>
<s5>05</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Subtipo</s0>
<s5>05</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Vaccination</s0>
<s5>06</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Vaccination</s0>
<s5>06</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Vacunación</s0>
<s5>06</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Afrique</s0>
<s2>NG</s2>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Africa</s0>
<s2>NG</s2>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Africa</s0>
<s2>NG</s2>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Infection</s0>
<s5>08</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Infection</s0>
<s5>08</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Infección</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Virus grippal A(H1N1)</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Influenzavirus A(H1N1)</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fN21><s1>035</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 13-0059247 INIST</NO>
<ET>2009 Pandemic Influenza A Virus Subtype H1N1 Vaccination in Africa-Successes and Challenges</ET>
<AU>MIHIGO (Richard); VIVAS TORREALBA (Claudia); CONINX (Kanokporn); NSHIMIRIMANA (Deo); KIENY (Marie Paule); CARRASCO (Peter); HEDMAN (Lisa); WIDDOWSON (Marc-Alain); KATZ (Mark A.); SCHOUB (Barry D.); HERAUD (Jean-Michel); WIDDOWSON (Marc-Alain)</AU>
<AF>World Health Organization Regional Office for Africa/Brazzaville/Congo (1 aut., 4 aut.); World Health Organization/Geneva/Suisse (2 aut., 3 aut., 5 aut., 6 aut., 7 aut.); Centers for Disease Control and Prevention/Atlanta/Géorgie (8 aut.); Global Disease Detection Division,  Centers for Disease Control and Prevention/Nairobi/Kenya (1 aut.); University of the Witwatersrand/Johannesburg/Afrique du Sud (2 aut.); National Influenza Center, Institut Pasteur de Madagascar/Antanarivo/Madagascar (3 aut.); Centre for Vaccines and Immunology, National Institute for Communicable Diseases, National Health Laboratory Service/Johannesburg/Afrique du Sud (2 aut.); International Epidemiology and Research Team, Epidemiology and Prevention Branch Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention/Atlanta, GA/Etats-Unis (4 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>The Journal of infectious diseases; ISSN 0022-1899; Coden JIDIAQ; Royaume-Uni; Da. 2012; Vol. 206; No. SUP1; S22-S28; Bibl. 17 ref.</SO>
<LA>Anglais</LA>
<EA>To provide vaccination against infection due to 2009 pandemic influenza A virus subtype H1N1 (A[H1N1] pdm09) to resource-constrained countries with otherwise very little access to the A(H1N1)pdm09 vaccine, the World Health Organization (WHO) coordinated distribution of donated vaccine to selected countries worldwide, including those in Africa. From February through November 2010, 32.2 million doses were delivered to 34 countries in Africa. Of the 19.2 million doses delivered to countries that reported their vaccination activities to WHO, 12.2 million doses (64%) were administered. Population coverage in these countries varied from 0.4% to 11%, with a median coverage of 4%. All countries targeted pregnant women (median proportion of all vaccine doses administered [mpv], 21% [range, 4%-72%]) and healthcare workers (mpv, 9% [range, 1%-73%]). Fourteen of 19 countries targeted persons with chronic conditions (mpv, 26% [range, 5%-66%]) and 10 of 19 countries vaccinated children (mpv, 54% [range, 17%-75%]). Most vaccine was distributed after peak A(H1N1)pdm09 transmission in the region. The frequency and severity of adverse events were consistent with those recorded after other inactivated influenza vaccines. Pandemic preparedness plans will need to include strategies to ensure more-rapid procedures to identify vaccine supplies and distribute and import vaccines to countries that may bear the brunt of a future pandemic.</EA>
<CC>002A05; 002B05</CC>
<FD>Soustype; Vaccination; Afrique; Infection; Virus grippal A(H1N1)</FD>
<ED>Subtype; Vaccination; Africa; Infection; Influenzavirus A(H1N1)</ED>
<SD>Subtipo; Vacunación; Africa; Infección</SD>
<LO>INIST-2052.354000505499230030</LO>
<ID>13-0059247</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000403 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000403 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    PandemieGrippaleV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:13-0059247
   |texte=   2009 Pandemic Influenza A Virus Subtype H1N1 Vaccination in Africa-Successes and Challenges
}}

This area was generated with Dilib version V0.6.34.
Data generation: Wed Jun 10 11:04:28 2020. Site generation: Sun Mar 28 09:10:28 2021

	Serveur d'exploration sur les pandémies grippales
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les pandémies grippales

2009 Pandemic Influenza A Virus Subtype H1N1 Vaccination in Africa-Successes and Challenges

2009 Pandemic Influenza A Virus Subtype H1N1 Vaccination in Africa-Successes and Challenges

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri